CLINICAL_TRIALS ClinicalTrials.gov record update

Phase I Study of Cellular ImmunoTx Using Memory Enriched T Cells Lentivirally Transduced to Express an IL13Rα2-Specific, Hinge-Optimized, 41BB-Costimulatory Chimeric Receptor and a Truncated CD19 for Pts With Rec/Ref MaligGlioma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02208362
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:22.834611+00:00
Published At: 2024-10-30T00:00:00+00:00
Record Updated At: 2025-09-03
Results Posted At: 2024-10-30
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Recurrent Glioblastoma", "Recurrent Malignant Glioma", "Recurrent WHO Grade II Glioma", "Recurrent WHO Grade III Glioma", "Refractory Glioblastoma", "Refractory Malignant Glioma", "Refractory WHO Grade II Glioma", "Refractory WHO Grade III Glioma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-09-03"
protocolSection.identificationModule.nctId: "NCT02208362"
protocolSection.identificationModule.officialTitle: "Phase I Study of Cellular ImmunoTx Using Memory Enriched T Cells Lentivirally Transduced to Express an IL13R\u03b12-Specific, Hinge-Optimized, 41BB-Costimulatory Chimeric Receptor and a Truncated CD19 for Pts With Rec/Ref MaligGlioma"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2024-10-30"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.